Baillie Gifford & Co’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-430,242
Closed -$127M 276
2026
Q1
$127M Sell
430,242
-15,794
-4% -$4.69M 0.13% 114
2025
Q4
$122M Sell
446,036
-11,386
-2% -$3.09M 0.1% 118
2025
Q3
$124M Sell
457,422
-13,215
-3% -$3.6M 0.09% 118
2025
Q2
$130M Buy
470,637
+15,994
+4% +$4.35M 0.1% 119
2025
Q1
$121M Buy
454,643
+57,699
+15% +$14.2M 0.11% 120
2024
Q4
$92.2M Buy
396,944
+35,775
+10% +$8.23M 0.07% 125
2024
Q3
$79.7M Buy
+361,169
New +$74.7M 0.06% 129

Other funds holding CME

Baillie Gifford & Co's CME Position: Q2 2026 in Review

Baillie Gifford & Co sold out of CME Group (CME) in Q2 2026, closing a stake of 430,242 shares — an estimated $127M sold.

Baillie Gifford & Co first reported a position in CME in Q3 2024 and held it in 7 quarters. The position peaked at $130M in Q2 2025. 956 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • Baillie Gifford & Co reported no remaining CME Group position as of Q2 2026 after selling out during the quarter.
  • Baillie Gifford & Co sold 430,242 CME Group shares in Q2 2026, an estimated $127M.
  • Baillie Gifford & Co first reported a position in CME Group in Q3 2024 and held it in 7 quarters.
  • Baillie Gifford & Co's CME Group position peaked at $130M in Q2 2025.
  • 956 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.